Autoimmunization and the Autoimmune Hemolytic Anaemias

Concurrent Atypical Hemolytic Uremic Syndrome and Autoimmune Hemolytic Anemia: a case report

Background: Atypical hemolytic uremic syndrome (aHUS) is a life-threatening and scarce disorder characterized by acute renal failure and disease, non-immune microangiopathic hemolytic anemia and thrombocytopenia, leading to end-stage renal failure or death, and consequently maybe accompanying by extra renal manifestations. Case report: We reported aHUS accompanied by autoimmune hemolytic anemi...

Latent autoimmune hemolytic syndrome.

The direct anti-globulin test was performed at random on 310 hospitalized patients with various diseases. Thirty-three patients were positive to anti-globulin test without any evidence of manifest autoimmune hemolytic anemia. Hematologic and erythrokinetic studies on these patients with latent autoim mune hemolytic syndrome revealed that their slight anemia was secondary anemia due to their bas...

Autoimmune Hemolytic Anemia

Thymoma with Autoimmune Hemolytic Anemia

A 38-year-old Japanese male was referred to our hospital with abnormal chest X-ray results and severe Coombs-positive hemolytic anemia. He was diagnosed with a stage IV, WHO type A thymoma and was treated with oral prednisolone (1 mg/kg/day) and subsequent chemotherapy. After chemotherapy, the patient underwent surgical resection of the thymoma. Hemolysis rapidly disappeared and did not return ...

Immunotherapy-associated autoimmune hemolytic anemia

BACKGROUND Immunotherapy has been widely used in the treatment of several solid and hematologic malignancies. Checkpoint inhibitors have been the forefront of cancer immunotherapy in recent years. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death 1 (PD-1) pathway are the prototypic checkpoint targets for immunotherapy. When combined, CTLA-4 and PD-1 checkpoint inhib...